FDA lifts partial clinical hold on Iovance's IOV-LUN-202 trial for LN-145 TIL cell therapy in non-small cell lung cancer, allowing patient enrollment resumption.
Iovance Biotherapeutics announces that the US FDA has lifted a partial clinical hold on the IOV-LUN-202 trial, investigating LN-145 TIL cell therapy in non-small cell lung cancer. The FDA cleared Iovance to resume patient enrollment after collaboration with the company and an independent data monitoring committee to develop additional safety measures and monitoring. The IOV-LUN-202 trial is evaluating LN-145 as a late-line option for certain patients with NSCLC.
March 04, 2024
6 Articles